Real-world treatment patterns, survival, health resource use and costs among Medicare beneficiaries with diffuse large B-cell lymphoma
Abstract
Aim: To examine real-world treatment patterns, survival, healthcare resource use and costs in elderly Medicare beneficiaries with diffuse large B-cell lymphoma (DLBCL). Methods: 11,880 Medicare patients aged ≥66 years with DLBCL between 1 October 2015 and 31 December 2018 were followed for ≥12 months after initiating front-line treatment. Results: Two-thirds (61.2%) of the patients received standard-of-care R-CHOP as first-line treatment. Hospitalization was common (57%) in the 12-months after initiation of 1L treatment; the mean DLCBL-related total costs were US$84,416 during the same period. Over a median follow-up of 2.1 years, 17.8% received at least 2L treatment. Overall survival was lower among later lines of treatment (median overall survival from initiation of 1L: not reached; 2L: 19.9 months; 3L: 9.8 months; 4L: 5.5 months). Conclusion: A large unmet need exists for more efficacious and well-tolerated therapies for older adults with DLBCL.
Plain language summary – Older patients with DLBCL need more effective treatments
Diffuse large B-cell lymphoma (DLBCL) is the most common form of Non-Hodgkin lymphoma, and it becomes more common with age. While researchers continue to develop newer, more effective treatments for DLBCL, it is important to understand how patients use existing treatments and the associated costs, particularly among the elderly. In our real-world analysis of nearly 12,000 older patients with DLBCL, we found high rates of hospitalization and hospice use, short length of life in later lines of therapy and substantial healthcare costs. Our findings suggest a large current unmet need for more effective and well-tolerated therapies for older adults with DLBCL in both the front-line and relapse/refractory settings.
Tweetable abstract
A real-world analysis of nearly 12,000 elderly patients with DLBCL observed high rates of hospitalization and hospice use, poor overall survival in later lines of therapy and substantial healthcare costs, suggesting a large unmet need.
Papers of special note have been highlighted as: • of interest
References
- 1. . Epidemiology of Non-Hodgkin's Lymphoma. Med. Sci. 9(1), 5 (2021).
- 2. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 116(12), 2040–2045 (2010).
- 3. . Relapsed/refractory diffuse large B-cell lymphoma. Hematol. Am. Soc. Hematol. Educ. Program. 2011, 498–505 (2011).
- 4. . Diffuse large B-cell lymphoma: r-CHOP failure-what to do? Hematol. Am. Soc. Hematol. Educ. Program. 2016(1), 366–378 (2016).
- 5. Second-line therapy in diffuse large B-cell lymphoma (DLBCL): treatment patterns and outcomes in older patients receiving outpatient chemotherapy. Leuk. Lymphoma 58(5), 1094–1104 (2017). • Relevant comparable study that examined elderly diffuse large B-cell lymphoma. Patients using older (2000–2007) Surveillance, Epidemiology and End Results (SEER)-Medicare data.
- 6. . Costs of relapsed diffuse large B-cell lymphoma among Medicare patients. Leuk. Lymphoma 59(12), 2880–2887 (2018). • Relevant prior study using older Medicare data (2010–2014) that similarly found high healthcare costs, particularly in relapsed/refractory setting.
- 7. . Temporal trends in treatment and survival of older adult diffuse large B-Cell lymphoma patients in the SEER-Medicare linked database. Leuk. Lymphoma 60(13), 3235–3243 (2019). • Relevant prior study using 2001–2013 SEER-Medicare data which also found very low stem cell transplant use by older patients.
- 8. . Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br. J. Cancer 105(11), 1684–1692 (2011).
- 9. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. Lancet Oncol. 14(6), 525–533 (2013).
- 10. Comorbidity is an independent prognostic factor in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP: a population-based cohort study. Br. J. Haematol. 165(4), 489–496 (2014).
- 11. Chronic Conditions Data Warehouse. Centers for Medicare and Medicaid Services (2023). www2.ccwdata.org
- 12. Economic burden of patients with diffuse large B-cell and follicular lymphoma treated in the USA. Future Oncol. Lond. Engl. 14(25), 2627–2642 (2018). • Relevant study of a commercially-insured population which found similarly high annual healthcare costs.
- 13. Real-World Characteristics, Treatment Patterns, Health Care Resource Use, and Costs of Patients with Diffuse Large B-Cell Lymphoma in the US The Oncologist. 26(5), e817–e826 (2021). • Important comparator study in a commercially-insured population that found comparable treatment patterns and costs of care.
- 14. Assessing unmet need among elderly Medicare Beneficiaries with Mantle cell lymphoma: an analysis of treatment patterns, survival, healthcare resource utilization, and costs. Leuk. Lymphoma 64(11), 1752–1770 (2023).
- 15. SAS Institute. SAS: Analytics, Artificial Intelligence and Data Management | SAS. www.sas.com/en_us/home.html
- 16. . Direct Costs Associated with Relapsed Diffuse Large B-Cell Lymphoma Therapies. The Oncologist. 24(9), 1229–1236 (2019).
- 17. . Economic burden and treatment patterns for patients with diffuse large B-cell lymphoma and follicular lymphoma in the USA. J. Comp. Eff. Res. 8(6), 393–402 (2019).
- 18. The economic burden to payers of patients with diffuse large B-cell lymphoma during the treatment period by line of therapy. Leuk. Lymphoma 61(7), 1601–1609 (2020).
- 19. . Challenges and Opportunities in the Management of Diffuse Large B-Cell Lymphoma in Older Patients. The Oncologist. 26(2), 120–132 (2021).
- 20. Autologous stem cell transplantation in elderly patients (> or = 60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registry. Haematologica 93(12), 1837–1842 (2008).
- 21. . Outcomes of auto-SCT for lymphoma in subjects aged 70 years and over. Bone Marrow Transplant. 46(9), 1219–1225 (2011).
- 22. Oncologist volume and outcomes in older adults diagnosed with diffuse large B cell lymphoma. Cancer 124(21), 4211–4220 (2018).
- 23. . Seven in Ten Medicare Beneficiaries Did Not Compare Plans During Past Open Enrollment Period. KFF (2021). www.kff.org/medicare/issue-brief/seven-in-ten-medicare-beneficiaries-did-not-compare-plans-during-past-open-enrollment-period/
